Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies

Journal of Medical Economics

Volumn 18, Issue 11, 2015, Pages 974-989

  Deng, Jing ^a   Gu, Shuyan ^b   Shao, Hui ^c   Dong, Hengjin ^b   Zou, Dajin ^d   Shi, Lizheng ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TULANE UNIVERSITY   (United States)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cardiff model; Cost effectiveness; Exenatide; Insulin glargine; Type 2 diabetes mellitus (T2DM)

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; VENOM;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; AGED; CHINA; COMBINATION DRUG THERAPY; COMORBIDITY; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; ECONOMICS; MIDDLE AGED;

ADULT; AGED; CHINA; COMORBIDITY; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; MIDDLE AGED; PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; VENOMS;

EID: 84945461419     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1067622     Document Type: Article

References (58)

1. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1987-2015
2. (WHO) WHO. Noncommunicable Disease (NCD) Country Profile China 2014. Geneva, Switzerland, 2015 http://www.who.int/nmh/countries/chn-en.pdf. Accessed on May 24, 2015
3. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59
4. CDS. China Guideline for Type 2 Diabetes. 2010. Beijing, China, 2010 http://www.cdschina.org/x-uploadfiles/dm201otaolungao.pdf. Accessed on May 24, 2015
5. Association AD. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(1 Suppl):S11
6. Wang W, McGreevey WP, Fu C, et al. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009;15:593-601
7. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2224-60
8. James WPT, Jackson-Leach R, Mhurchu CN, et al. Overweight and obesity (high body mass index). Comparative quantification of health risks: global and regional burden of disease attribution to selected major risk factors. WHO 2004;1:497-596
9. Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Invest 2013;4:53-61
10. Chiquette E, Toth PP, Ramirez G, et al. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag 2012;8:621
11. Inc AP. exenatide injection [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc; 2009 BYETTA
12. Du Y-J. Controlled clinical research of poor glycemic control in type 2 diabetes treating with exenatide and insulin glargine. Pract Pharm Clin Remed 2014;17:583-7
13. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
14. Karagianni P, Polyzos S, Kartali N, et al. Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. Adv Med Sci 2013; 58:38-43
15. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Therapeut 2007; 29:2333-48
16. Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. Eur J Intern Med 2014;25:407-14
17. Li W-X, Gou J-F, Tian J-H, et al. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Curr Therapeut Res 2010;71:211-38
18. Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-69
19. Liu S, Zhao Y, Hempe JM, et al. Economic burden of hypoglycemia in patients with Type 2 diabetes. Exp Rev Pharmacoecon Outcomes Res 2012;12:47-51
20. Goodall G, Costi M, Timlin L, et al. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinol Nutr (English Edition) 2011;58:331-40
21. Mittendorf T, Smith-Palmer J, Timlin L, et al. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obes Metab 2009;11:1068-79
22. Brändle M, Erny-Albrecht K, Goodall G, et al. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int j clin pharmacol therapeut 2009;47:501-15
23. Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22
24. Woehl A, Evans M, Tetlow AP, et al. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol 2008;7:24
25. Palmer J, Pinto C, Duarte R, et al. PDB51 cost-effectiveness of exenatide versus insulin glargine and versus biphasic insulin aspart for the treatment of type 2 diabetes in Portugal: a long-term health economic analysis. Value Health 2010;13:A293
26. Bruhn D, Malhan S, Kavuncubasi S, et al. PDB27 cost-effectiveness of exenatide versus insulin glargine for the treatment of type-2 diabetes in Turkey: a long-term health economic analysis. Value Health 2009;12:A406
27. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
28. Mount H. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638
29. Palmer AJ. Computer modeling of diabetes and its complications: a report onthe fifth Mount Hood challenge meeting. Value Health 2013;16:670-85
30. Clarke P, Gray A, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
31. China Minister of Health. Chinese Health Statistics Yearbook. Beijing: Chin Minister of Health, 2013
32. Xian S, Ting-qi Z. Effects of exenatide on glycemic control over 52 weeks in patients with type 2 diabetes. Chin Pharm J 2014;49:941-3
33. Han W. Initial observation of exenatide for treatment of type 2 diabetes. J Qinghai Univ 2011;10:22-3
34. Xu H, Lu L, He Y, et al. Clinical efficacy of exenatide treating type 2 diabetes patients who are not well controlled by oral antiglycemia drugs. Chin J Prim Med Pharm 2014;1:1378-9
35. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual life Res 2007;16:1251-65
36. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 2008;11:478-86
37. Lane S, Levy A, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
38. Hui G, Jun L, Zhongli J. Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medicla costs in type 2 diabetes patients. Chin J Rehab Med 2007;22:395-8
39. Ya-ming Z, Jing W, Kun X. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Service Administration 2012;32:1195-8
40. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
41. Bureau of Zhejiang Province Pharmacy. Government Regulated Highest Retail Price. 2004-2013. Zhejiang Provincial Government, Zhejiang Province, 2013. http://www.zjpi.gov.cn/main/html/2013/CT10138/4c69032c8e3344f98c 29388cdd8390fe.html. Accessed on September 15, 2014
42. Kangdele Pharmacy. Kangdele Pharmacy Retail Price. 2014. Available from: http://www.baiji.com.cn/goods-6710.html. Accessed on September 15, 2014
43. Xing-yun H, Zhun Z, Xia T, et al. Cost-effetiveness analysis of 2 dosage forms of metformin hydrochloride in the treatment of type 2 diabetes. China Pharm 2014;25:1844-7
44. Gao L, Zhao F-L, Li S-C. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012;28:436-44
45. China NBoSo. General CPI for all the years. Beijing, 2015. http://data.stats.- gov.cn/workspace/index?a=q&type=global&dbcode=hgnd&m= hgnd&dimension=zb&code=A090101®ion=000000&time. Accessed on May 24, 2015
46. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22:340-9
47. China NBoSo. GDP per capita National Data. Beijing, 2013
48. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes A randomized trial. Ann Intern Med 2005;143:559-69
49. Pawaskar M, Anderson J, Zagar A. PDB18 cost offsets associated with use of exenatide compared to glargine for the treatment of patients with type 2 diabetes. Value Health 2009;12:A404
50. Currie CJ, McEwan P, Peters JR, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90
51. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
52. Palmera AJ, Rozea S, Valentinea WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(1 Suppl):S27-40
53. Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013;126:925. e11-e22
54. China GAoSo. 2010 National Physical Condition Monitoring Report. Beijing, 2010. http://www.sport.gov.cn/n16/n1077/n297454/2052709.html. Accessed on May 24, 2015
55. Li H, Xu F, Wang F. Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chin J New Drugs 2011;1:2163-70
56. Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008;25:752-74
57. Zheng Y, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus. Hefei, China: Chinese Rural Health Service Administration, 2012. pp. 1195-8
58. Jaime Caro J, Ozer Stillman I, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007;10:239-54